0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Clinicopathologic Reports, Case Reports, and Small Case Series |

Cherry Red Spot in Sialidosis (Mucolipidosis Type I) FREE

J. Wesley Heroman, MD; Paul Rychwalski, MD; Charles C. Barr, MD
[+] Author Affiliations

Section Editor: W. Richard Green, MD

More Author Information
Arch Ophthalmol. 2008;126(2):270-271. doi:10.1001/archophthalmol.2007.31.
Text Size: A A A
Published online

The differential diagnosis of a cherry red spot in the macula includes central retinal artery occlusion and metabolic storage diseases such as Tay-Sachs disease, Sandhoff disease, Niemann-Pick disease, Fabry disease, Gaucher disease, and sialidosis. We report a case of an adolescent who, at a routine ophthalmic examination, was found to have a cherry red spot in the maculae of both eyes. Laboratory investigation results showed that the patient had mucolipidosis type I, which is a rare lysosomal storage disease with clinical and histologic findings similar to the mucopolysaccharidoses and the sphingolipidoses.

A 14-year-old white boy complained of difficulty seeing the blackboard at school. A screening eye examination found decreased distance vision in both eyes. He was of normal intelligence and his medical history was significant only for scoliosis and seasonal allergies. Visual acuity corrected to 20/20 OU. Results of a dilated ophthalmoscopic examination revealed a cherry red spot in both maculae (Figure). Fluorescein angiography demonstrated hypofluorescence around the foveal area in the midvenous phase (eFigure 1). There was relative hyperfluorescence in the foveal area, but this was believed to represent a normal fluorescein pattern, rather than pigment epithelial disease. Optical coherence tomography showed increased reflectivity of the inner retinal layers, corresponding to the hypofluorescence on the fluorescein angiogram (eFigure 2). Because of the patient's normal visual acuity, symmetric changes, and lack of symptoms, we suspected a metabolic storage disorder. Laboratory test results showed normal levels of β-galactosidase, arylsulfatase A, hexosaminidase A and B, and β-galactocerebrosidase. However, sialic acid levels were elevated in the urine. Examination results of a skin biopsy specimen revealed a fibroblast α-neuraminidase level of 0.5 nmoles/h per milligram of protein (reference range, 15.0-30.0 nmoles/h per milligram of protein). Based on these findings, a diagnosis of sialidosis (mucolipidosis type I) was made.

Place holder to copy figure label and caption
Figure.

Color fundus photographs of the right (A) and left (B) eyes demonstrating the classic appearance of a cherry red spot in the maculae.

Graphic Jump Location

Sialidosis (mucolipidosis type I) is a rare inherited lysosomal storage disease characterized by deficiency of α-N-acetylneuraminidase (sialidase) in leukocytes and cultured fibroblasts.1This results in intracellular storage of excess sialyloligosaccharides and is histologically observed as abnormal vacuolization of various cell types. Two major phenotypes of mucolipidosis exist: type I or the cherry red spot myoclonus syndrome, and a more severe infantile form, type II. Sialidosis has an autosomal recessive pattern of inheritance, and the gene has been localized on chromosome 6p21.2It occurs in 1 of every 2 200 000 live births. Patients with type II disease have somatic changes, characterized by coarse facies, hepatolomegaly, bony changes of dysostosis multiplex, and developmental delay. Patients with type II disease usually die within the first 2 years (congenital form) or by the second decade (infantile form) of life.3By contrast, patients with type I disease are less severely affected and typically develop symptoms of myoclonic epilepsy, visual problems, and ataxia in the second or the third decade of life.4Macular cherry red spots are always present and, therefore, sialidosis should be included in the differential diagnosis of a cherry red macula in this clinical setting. Diagnostic evaluation for a patient with a cherry red spot in the macula not due to arterial occlusion should include a genetic history and an appropriate laboratory workup to confirm the underlying cause.

We herein present a rare case of a 14-year-old boy with mucolipidosis type I who had cherry red spots in the maculae of both eyes. The patient had minimal symptoms and visual acuity correctable to 20/20 OU. Of interest in this case are the fluorescein angiogram and optical coherence tomogram findings. The fluorescein angiogram shows blocked fluorescence surrounding the fovea throughout the angiogram (eFigure 1). The optical coherence tomogram shows increased reflectivity in the ganglion cell layer corresponding to the blocked fluorescence (eFigure 2). Although pathological confirmation is lacking in this case, a previous autopsy report of a patient with mucolipidosis type I demonstrated diffuse intracytoplasmic accumulation of lipofuscinlike pigment in the cerebral neurons.5This leads us to speculate that the ophthalmoscopic changes observed in our patient are due to an accumulation of sialyloligosaccharides in the inner layers of the retina.

Correspondence:Dr Barr, Department of Ophthalmology and Visual Sciences, University of Louisville, 301 E Muhammad Ali Blvd, Louisville, KY 40202 (ccbarr@pol.net).

Financial Disclosure:None reported.

Cantz  MGehler  JSpranger  J Mucolipidosis I: increased sialic acid content and deficiency of an α-N-acetylneuraminidase in cultured fibroblasts. Biochem Biophys Res Commun 1977;74 (2) 732- 738
PubMed Link to Article
Sphranger  JGehler  JCantz  M Mucolipidosis I: a sialidosis. Am J Med Genet 1977;1 (1) 21- 29
PubMed Link to Article
Till  JSRoach  EBurton  B Sialidosis (neuraminidase deficiency) types I and II: neuro-ophthalmic manifestations. J Clin Neuroophthalmol 1987;7 (1) 40- 44
PubMed
Federico  ACecio  ABattini  GAMichalski  JCStrecker  GGuazzi  GC Macular cherry-red spot and myoclonus syndrome: juvenile form of sialidosis. J Neurol Sci 1980;48 (2) 157- 169
PubMed Link to Article
Allegranza  ATredici  GMarmiroli  Pdi Donato  SFranceschetti  SMariani  C Sialidosis type I: pathological study in an adult. Clin Neuropathol 1989;8 (6) 266- 271
PubMed

Figures

Place holder to copy figure label and caption
Figure.

Color fundus photographs of the right (A) and left (B) eyes demonstrating the classic appearance of a cherry red spot in the maculae.

Graphic Jump Location

Tables

References

Cantz  MGehler  JSpranger  J Mucolipidosis I: increased sialic acid content and deficiency of an α-N-acetylneuraminidase in cultured fibroblasts. Biochem Biophys Res Commun 1977;74 (2) 732- 738
PubMed Link to Article
Sphranger  JGehler  JCantz  M Mucolipidosis I: a sialidosis. Am J Med Genet 1977;1 (1) 21- 29
PubMed Link to Article
Till  JSRoach  EBurton  B Sialidosis (neuraminidase deficiency) types I and II: neuro-ophthalmic manifestations. J Clin Neuroophthalmol 1987;7 (1) 40- 44
PubMed
Federico  ACecio  ABattini  GAMichalski  JCStrecker  GGuazzi  GC Macular cherry-red spot and myoclonus syndrome: juvenile form of sialidosis. J Neurol Sci 1980;48 (2) 157- 169
PubMed Link to Article
Allegranza  ATredici  GMarmiroli  Pdi Donato  SFranceschetti  SMariani  C Sialidosis type I: pathological study in an adult. Clin Neuropathol 1989;8 (6) 266- 271
PubMed

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 3

Related Content

Customize your page view by dragging & repositioning the boxes below.

Related Collections
PubMed Articles